141 related articles for article (PubMed ID: 14579809)
1. Protection for manufacturing, not research.
Nat Rev Drug Discov; 2003 Oct; 2(10):766. PubMed ID: 14579809
[No Abstract] [Full Text] [Related]
2. Should the patent system for new medicines be abolished?
DiMasi JA; Grabowski HG
Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
[No Abstract] [Full Text] [Related]
3. Razing the tollbooths. A call for restricting patents on basic biomedical research.
Stix G
Sci Am; 2003 Apr; 288(4):37. PubMed ID: 12661312
[No Abstract] [Full Text] [Related]
4. Science and the law. Working through the patent problem.
Walsh JP; Cohen WM; Arora A
Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928
[No Abstract] [Full Text] [Related]
5. Justices expand rights to experiment with patented drugs.
Pollack A
N Y Times Web; 2005 Jun; ():C1, C8. PubMed ID: 15966121
[No Abstract] [Full Text] [Related]
6. Using market-exclusivity incentives to promote pharmaceutical innovation.
Kesselheim AS
N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
[No Abstract] [Full Text] [Related]
7. [Patent rights and the free research. The boundary between basic research and private sector is not longer razor-sharp].
Westerlund L
Lakartidningen; 2005 Sep 26-Oct 2; 102(39):2737. PubMed ID: 16245544
[No Abstract] [Full Text] [Related]
8. Intellectual property. Fixing the legal framework for pharmaceutical research.
Knowles SM
Science; 2010 Feb; 327(5969):1083-4. PubMed ID: 20150445
[No Abstract] [Full Text] [Related]
9. Protect pharmaceutical innovation.
Musselwhite LW; Andrews J
Science; 2010 Jun; 328(5984):1354; author reply 1354-5. PubMed ID: 20538934
[No Abstract] [Full Text] [Related]
10. Enforcing pharmaceutical and biotech patent rights in China.
Zhang YP; Deng MM
Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760
[No Abstract] [Full Text] [Related]
11. Biotechnology products and university-based science.
Sobolski GK
JAMA; 2005 Jun; 293(23):2862; author reply 2863. PubMed ID: 15956629
[No Abstract] [Full Text] [Related]
12. "Obvious to try": a proper patentability standard in the pharmaceutical arts?
Trask AV
Fordham Law Rev; 2008 Apr; 76(5):2625-68. PubMed ID: 18546581
[No Abstract] [Full Text] [Related]
13. Biotechnology products and university-based science.
Korn D; Heinig SJ
JAMA; 2005 Jun; 293(23):2862-3; author reply 2863. PubMed ID: 15956628
[No Abstract] [Full Text] [Related]
14. Safe harbors in Europe: an update on the research and Bolar exemptions to patent infringement.
Kupecz A; Roox K; Dekoninck C; Schertenleib D; Stief M; Sanna F; Orsingher M; Miralles S; Molina E; Crosse T; Gilbert M; James W
Nat Biotechnol; 2015 Jul; 33(7):710-5. PubMed ID: 26154008
[No Abstract] [Full Text] [Related]
15. Gene patenting and medical research: a view from a pharmaceutical company.
Stott M; Valentine J
Nat Rev Drug Discov; 2004 Apr; 3(4):364-8. PubMed ID: 15060532
[No Abstract] [Full Text] [Related]
16. Gene patents--a pharmaceutical perspective.
Tribble JL
Camb Q Healthc Ethics; 1998; 7(4):429-32. PubMed ID: 9752585
[No Abstract] [Full Text] [Related]
17. U.S. patent law. Case probes what's fair game in the search for new drugs.
Kintisch E
Science; 2005 Apr; 308(5719):174. PubMed ID: 15821048
[No Abstract] [Full Text] [Related]
18. Navigating US conflict-of-interest rules when commercializing research.
Otrompke J
Nat Biotechnol; 2004 Jul; 22(7):921-4. PubMed ID: 15259191
[No Abstract] [Full Text] [Related]
19. Biotechnology products and university-based science.
Lempert P
JAMA; 2005 Jun; 293(23):2861-2; author reply 2863. PubMed ID: 15956627
[No Abstract] [Full Text] [Related]
20. Patent highlights December 2019-January 2020.
Mucke HA
Pharm Pat Anal; 2020 May; 9(3):67-74. PubMed ID: 32539539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
